{"id":"NCT01790685","sponsor":"Johns Hopkins University","briefTitle":"Ozurdex for Retinal Vein Occlusion Study (ORVO Study)","officialTitle":"Ozurdex for Retinal Vein Occlusion Study (ORVO Study)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-02","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2013-02-13","resultsPosted":"2015-04-03","lastUpdate":"2015-04-22"},"enrollment":40,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Retinal Vein Occlusion"],"interventions":[{"type":"DRUG","name":"dexamethasone implant","otherNames":["Ozurdex"]}],"arms":[{"label":"CRVO","type":"OTHER"},{"label":"BRVO","type":"OTHER"}],"summary":"To measure the pro-permeability factors in the aqueous humor of patients with persistent/recurrent macular edema after an injection of Ozurdex.","primaryOutcome":{"measure":"Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex","timeFrame":"4 months","effectByArm":[{"arm":"CRVO","deltaMin":7,"sd":null},{"arm":"BRVO","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":23},"commonTop":["Increase in IOP in study eye","Redness of study eye after drug injection","Patient had an uneventful fall"]}}